Skip to main content
Premium Trial:

Request an Annual Quote

Progenity: Sean Lavin

Progenity announced that Sean Lavin has been appointed as VP of business development, strategy, and investor relations. He will work with the company's senior management on strategy, business development, investor outreach, and shareholder value creation. He runs his own firm, Alpha Lavin Advisors, that focuses on value creation in the medical device and diagnostic sectors. Lavin previously served as a managing director in equity research at BTIG and Lazard Capital Markets covering these sectors. He joined Lazard in 2008 as the senior medical technology and diagnostic analyst and moved to BTIG as a senior healthcare analyst in 2013.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.